Immunotherapy of prostate cancer

Stephen J. Freedland; Allan J. Pantuck; Jeffrey Weider; Amnon Zisman; Arie S. Belldegrun

doi:10.1007/s11934-001-0086-9

Immunotherapy of prostate cancer

Stephen J. Freedland, Allan J. Pantuck, Jeffrey Weider, Amnon Zisman, Arie S. Belldegrun

Research output: Contribution to journal › Article › peer-review

Abstract

The realization that prostate cancer is an immunogenic tumor, in conjunction with the discovery of novel methods for priming the immune system to generate an antitumor response, has resulted in several new approaches for prostate cancer immunotherapy. Based on these various approaches, several human clinical trials have begun using immune-based therapies for prostate cancer. These approaches can be divided into cytokine-based therapies, tumor-associated antigen-based therapies, tumor vaccines, and dendritic cell-based therapies. This review summarizes the latest findings from each of these approaches and gives results from the few completed human clinical trials.

Original language	English
Pages (from-to)	242-247
Number of pages	6
Journal	Current Urology Reports
Volume	2
Issue number	3
DOIs	https://doi.org/10.1007/s11934-001-0086-9
State	Published - May 2001
Externally published	Yes

Keywords

Dendritic Cell
Epidermal Growth Factor Receptor
Human Clinical Trial
Prostatic Acid Phosphatase
Tumor Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11934-001-0086-9

Cite this

@article{5778308a4bb34054bccab146ecdceb8f,

title = "Immunotherapy of prostate cancer",

abstract = "The realization that prostate cancer is an immunogenic tumor, in conjunction with the discovery of novel methods for priming the immune system to generate an antitumor response, has resulted in several new approaches for prostate cancer immunotherapy. Based on these various approaches, several human clinical trials have begun using immune-based therapies for prostate cancer. These approaches can be divided into cytokine-based therapies, tumor-associated antigen-based therapies, tumor vaccines, and dendritic cell-based therapies. This review summarizes the latest findings from each of these approaches and gives results from the few completed human clinical trials.",

keywords = "Dendritic Cell, Epidermal Growth Factor Receptor, Human Clinical Trial, Prostatic Acid Phosphatase, Tumor Vaccine",

author = "Freedland, {Stephen J.} and Pantuck, {Allan J.} and Jeffrey Weider and Amnon Zisman and Belldegrun, {Arie S.}",

note = "Publisher Copyright: {\textcopyright} 2001, Current Science Inc.",

year = "2001",

month = may,

doi = "10.1007/s11934-001-0086-9",

language = "אנגלית",

volume = "2",

pages = "242--247",

journal = "Current Urology Reports",

issn = "1527-2737",

publisher = "Current Science, Inc.",

number = "3",

}

TY - JOUR

T1 - Immunotherapy of prostate cancer

AU - Freedland, Stephen J.

AU - Pantuck, Allan J.

AU - Weider, Jeffrey

AU - Zisman, Amnon

AU - Belldegrun, Arie S.

PY - 2001/5

Y1 - 2001/5

N2 - The realization that prostate cancer is an immunogenic tumor, in conjunction with the discovery of novel methods for priming the immune system to generate an antitumor response, has resulted in several new approaches for prostate cancer immunotherapy. Based on these various approaches, several human clinical trials have begun using immune-based therapies for prostate cancer. These approaches can be divided into cytokine-based therapies, tumor-associated antigen-based therapies, tumor vaccines, and dendritic cell-based therapies. This review summarizes the latest findings from each of these approaches and gives results from the few completed human clinical trials.

AB - The realization that prostate cancer is an immunogenic tumor, in conjunction with the discovery of novel methods for priming the immune system to generate an antitumor response, has resulted in several new approaches for prostate cancer immunotherapy. Based on these various approaches, several human clinical trials have begun using immune-based therapies for prostate cancer. These approaches can be divided into cytokine-based therapies, tumor-associated antigen-based therapies, tumor vaccines, and dendritic cell-based therapies. This review summarizes the latest findings from each of these approaches and gives results from the few completed human clinical trials.

KW - Dendritic Cell

KW - Epidermal Growth Factor Receptor

KW - Human Clinical Trial

KW - Prostatic Acid Phosphatase

KW - Tumor Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0035372397&partnerID=8YFLogxK

U2 - 10.1007/s11934-001-0086-9

DO - 10.1007/s11934-001-0086-9

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 12084272

AN - SCOPUS:0035372397

SN - 1527-2737

VL - 2

SP - 242

EP - 247

JO - Current Urology Reports

JF - Current Urology Reports

IS - 3

ER -

Immunotherapy of prostate cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this